News ORYX to Present Positive Clinical Data for Oncolytic Virus ParvOryx in Combination with Immune Modulators at CIMT Annual Meeting 2018 Positive data from Phase I/IIa clinical trial in glioblastoma with oncolytic virus ParvOryx published in peer-reviewed journal, Molecular Therapy ORYX to present positive clinical data with oncolytic virus ParvOryx in combination with immune activators at the Third CRI-CIMT-EATI-AACR Conference ORYX reports positive clinical evidence with oncolytic virus ParvOryx in combination with immuno-oncology drugs partnering360/Informa Pharma Intelligence: Interview with ORYX CEO on research partnerships and cancer vaccine studies ORYX Enrols First Patients in a Dose-Escalating Phase I/IIa Pilot Study with Oncolytic Virus ParvOryx to Treat Metastatic Pancreatic Cancer BioCentury: Infectious enthusiasm - How oncolytic viruses are coming of age in cancer immunotherapy combinations ORYX Enrols First Patients in an Additional Phase I Trial with Therapeutic Vaccine VicOryx to Treat HPV-Associated Cancers in Combination with Standard Chemotherapy ORYX' Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial to Treat Glioblastoma Multiforme ORYX Presents Positive Phase I/IIa Data with Therapeutic Vaccine MicOryx to Treat MSI-H Colorectal Cancers at ASCO 2015